Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -33.11% is 138% below its 5-year average of -13.89%, near the low end of its 5-year range (-38.99%–27.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 6.13% above its 12-month average of -35.27%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -33.11%.
RETURN ON EQUITY (ROE)
-33.11%
RETURN ON EQUITY (ROE) AVG TTM
-35.27%
RETURN ON EQUITY (ROE) AVG 3Y
-27.16%
RETURN ON EQUITY (ROE) AVG 5Y
-13.89%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+6.13%
CURRENT VS 3Y AVG
-21.90%
CURRENT VS 5Y AVG
-138.35%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · INDUSTRIALS
5.27%
median of 447 covered companies
CURRENT VS SECTOR MEDIAN
-728.20%
vs the sector median at left
BioNexus Gene Lab Corp.
Market Cap
$3.00M
Return on Equity (ROE)
-33.11%
TTM Avg
-35.27%
3Y Avg
-27.16%
5Y Avg
-13.89%
Market Cap
$2.98M
Return on Equity (ROE)
-13.25%
TTM Avg
-58.55%
3Y Avg
11.68%
5Y Avg
11.68%
Market Cap
$3.17M
Return on Equity (ROE)
-58.56%
TTM Avg
-112.90%
3Y Avg
-85.34%
5Y Avg
14.61%
Market Cap
$3.17M
Return on Equity (ROE)
-1120.89%
TTM Avg
-3198.65%
3Y Avg
-1619.41%
5Y Avg
-1096.38%
Market Cap
$2.74M
Return on Equity (ROE)
-33.54%
TTM Avg
-11.54%
3Y Avg
6.78%
5Y Avg
20.37%
Market Cap
$2.71M
Return on Equity (ROE)
3.24%
TTM Avg
16.35%
3Y Avg
84.34%
5Y Avg
74.71%
Market Cap
$2.66M
Return on Equity (ROE)
-76.99%
TTM Avg
-50.65%
3Y Avg
-44.51%
5Y Avg
-3.30%
Market Cap
$2.64M
Return on Equity (ROE)
-181.23%
TTM Avg
-333.49%
3Y Avg
36.39%
5Y Avg
-1.31%
Market Cap
$3.36M
Return on Equity (ROE)
-6.64%
TTM Avg
-21.97%
3Y Avg
-12.60%
5Y Avg
707.59%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioNexus Gene Lab Corp. (BGLC) | $3.00M | -33.11% | -35.27% | -27.16% | -13.89% |
| PTL Limited (PTLE)vs › | $2.98M | -13.25% | -58.55% | 11.68% | 11.68% |
| Iveda Solutions, Inc. (IVDA)vs › | $3.17M | -58.56% | -112.90% | -85.34% | 14.61% |
| Polar Power, Inc. (POLA)vs › | $3.17M | -1120.89% | -3198.65% | -1619.41% | -1096.38% |
| Intelligent Group Limited (INTJ)vs › | $2.74M | -33.54% | -11.54% | 6.78% | 20.37% |
| Globavend Holdings Limited (GVH)vs › | $2.71M | 3.24% | 16.35% | 84.34% | 74.71% |
| Top KingWin Ltd. Class A (DPU)vs › | $2.66M | -76.99% | -50.65% | -44.51% | -3.30% |
| DEFSEC Technologies Inc. (DFSC)vs › | $2.64M | -181.23% | -333.49% | 36.39% | -1.31% |
| Addentax Group Corp. (ATXG)vs › | $3.36M | -6.64% | -21.97% | -12.60% | 707.59% |
| INLIF Limited (INLF)vs › | $3.60M | -33.75% | -9.05% | 0.96% | 2.85% |
ROE
-33.1%
ROA
-29.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -33.11% |
| 2026-03-31 | -35.89% |
| 2025-12-31 | -34.64% |
| 2025-09-30 | -33.70% |
| 2025-06-30 | -38.99% |
| 2025-03-31 | -27.25% |
| 2024-12-31 | -19.20% |
| 2024-09-30 | -10.04% |
| 2024-06-30 | -23.11% |
| 2024-03-31 | -28.52% |
| 2023-12-31 | -27.23% |
| 2023-09-30 | -31.94% |
| 2023-06-30 | -9.44% |
| 2023-03-31 | -6.74% |
| 2022-12-31 | -5.34% |
| 2022-09-30 | -1.71% |
| 2022-06-30 | 3.85% |
| 2022-03-31 | 6.03% |
| 2021-12-31 | 10.47% |
| 2021-09-30 | 27.38% |
| 2021-06-30 | 27.45% |
| 2021-03-31 | 26.59% |
| 2020-12-31 | 38.08% |
| 2020-09-30 | 126.20% |
| 2020-06-30 | 94.79% |
| 2020-03-31 | 85.66% |
| 2019-12-31 | -21.96% |
| 2019-09-30 | -17.16% |
| 2019-06-30 | -20.42% |
| 2019-03-31 | -17.11% |
| 2018-12-31 | 5.29% |
| 2018-09-30 | 5.95% |
